Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

European Research Council grant · Running

ProtecTHY Protecting the thymic epithelial cells and thymopoiesis during hematopoietic stem cell transplantation

Coordinator
Helsingin Yliopisto, Finland
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€2.2m
Total cost
€2.2m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101164016

What the project is doing

In the project's own words, from its summary on CORDIS.

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a common, often last-resort treatment for haematological diseases, but it is plagued by long-term morbidity and high mortality. Direct alloHSCT-induced damage to the thymus and subsequent loss of thymopoiesis, ie the production of new T cells, is considered one of the main reasons for these complications. Our limited understanding of how the thymus is damaged during alloHSCT restricts the development of thymus-protecting protocols.

The goal of ProtecTHY is to unravel the intrinsic protective mechanisms of the human thymus and assess how alloHSCT affects them, with the ultimate objective of devising measures to prevent thymic damage. We take advantage of an innovative whole organ culture system for the human thymus developed in my laboratory and our extensive pre-existing collection of human thymus tissue samples spanning a diverse age range. ProtecTHY specifically aims to 1) discover how the thymus protects itself from external insults over the course of the human lifetime, 2) reveal how alloHSCT disrupts the human thymus microanatomy and how that damage can be prevented with a cellular therapy, and 3) examine how thymic damage affects the circulating true naive T cells and if existing clinical treatments for alloHSCT complications can restore the loss of thymopoiesis.

We will apply state-of-the-art spatial and single-cell multiomics to dissect these protective layers of the thymus both ex vivo and after alloreactive challenge in vitro. Moreover, by testing the effect of treatments already in clinical use, ProtecTHY can resolve their specific mechanisms of action and impact on the thymus. Our results are thus directly translatable to the human condition and can direct future treatments to enhance outcomes following alloHSCT.

As a translational immunologist and clinical microbiologist with extensive experience in human thymus research, I am well equipped to uncover the mechanisms of thymic protection.

Topics

Who is involved

OrganisationCityCountryRole
Helsingin YliopistoHelsinkiFinlandCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI